The US FDA has approved drugs for asthma (anti-IL-5 agents, including mepolizumab, reslizumab, benralizumab, and anti-IgE omalizumab); atopic dermatitis (anti-IL-4/IL-13 agent dupilumab), psoriasis (anti-IL-17 secukinumab and brodalumab), and chronic urticaria (anti-IgE and omalizumab). Here, IL5 is linked to atopic eczema.